Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Bsteh G, Hoepner R, Gernert JA, Berek K, Gradl C, Kliushnikova D, Damulina A, Traxler G, Föttinger F, Habernig S, Krajnc N, Betancourt AXL, Ponleitner M, Zrzavy T, Deisenhammer F, Di Pauli F, Havla J, Khalil M, Kümpfel T, Wipfler P, Chan A, Berger T, Hammer H, Hegen H. Bsteh G, et al. Among authors: hoepner r. Eur J Neurol. 2025 Jan;32(1):e16587. doi: 10.1111/ene.16587. Eur J Neurol. 2025. PMID: 39686558 Free PMC article.
Disability progression is a question of definition-A methodological reappraisal by example of primary progressive multiple sclerosis.
Bsteh G, Marti S, Krajnc N, Traxler G, Salmen A, Hammer H, Leutmezer F, Rommer P, Di Pauli F, Chan A, Berger T, Hegen H, Hoepner R. Bsteh G, et al. Among authors: hoepner r. Mult Scler Relat Disord. 2024 Dec 6;93:106215. doi: 10.1016/j.msard.2024.106215. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 39662164 Free article.
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez JF, Melie-Garcia L, Cagol A, Galbusera R, Subramaniam S, Lorscheider J, Galli E, Mueller J, Fischer-Barnicol B, Achtnichts L, Findling O, Lalive PH, Bridel C, Uginet M, Müller S, Pot C, Mathias A, Du Pasquier R, Salmen A, Hoepner R, Chan A, Disanto G, Zecca C, D'Souza M, Hemkens LG, Yaldizli Ö, Derfuss T, Roth P, Gobbi C, Brassat D, Tackenberg B, Pedotti R, Raposo C, Oksenberg J, Wiendl H, Berger K, Hermesdorf M, Piehl F, Conen D, Buser A, Kappos L, Khalil M, Granziera C, Abdelhak A, Leppert D, Willemse EAJ, Kuhle J; Swiss MS Cohort study (SMSC). Benkert P, et al. Among authors: hoepner r. Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096. Online ahead of print. Ann Neurol. 2024. PMID: 39411917
MultiSCRIPT-Cycle 1-a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial.
Janiaud P, Zecca C, Salmen A, Benkert P, Schädelin S, Orleth A, Demuth L, Maceski AM, Granziera C, Oechtering J, Leppert D, Derfuss T, Achtnichts L, Findling O, Roth P, Lalive P, Uginet M, Müller S, Pot C, Hoepner R, Disanto G, Gobbi C, Rooshenas L, Schwenkglenks M, Lambiris MJ, Kappos L, Kuhle J, Yaldizli Ö, Hemkens LG. Janiaud P, et al. Among authors: hoepner r. Trials. 2024 Sep 11;25(1):607. doi: 10.1186/s13063-024-08454-6. Trials. 2024. PMID: 39261900 Free PMC article.
Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort.
Greselin M, Lu PJ, Melie-Garcia L, Ocampo-Pineda M, Galbusera R, Cagol A, Weigel M, de Oliveira Siebenborn N, Ruberte E, Benkert P, Müller S, Finkener S, Vehoff J, Disanto G, Findling O, Chan A, Salmen A, Pot C, Bridel C, Zecca C, Derfuss T, Lieb JM, Diepers M, Wagner F, Vargas MI, Pasquier RD, Lalive PH, Pravatà E, Weber J, Gobbi C, Leppert D, Kim OC, Cattin PC, Hoepner R, Roth P, Kappos L, Kuhle J, Granziera C. Greselin M, et al. Among authors: hoepner r. Bioengineering (Basel). 2024 Aug 22;11(8):858. doi: 10.3390/bioengineering11080858. Bioengineering (Basel). 2024. PMID: 39199815 Free PMC article.
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
Bsteh G, Aicher ML, Walde JF, Krajnc N, Haider L, Traxler G, Gradl C, Salmen A, Riedl K, Poskaite P, Leyendecker P, Altmann P, Auer M, Berek K, Di Pauli F, Kornek B, Leutmezer F, Rommer PS, Zulehner G, Zrzavy T, Deisenhammer F, Chan A, Berger T, Hoepner R, Hammer H, Hegen H. Bsteh G, et al. Among authors: hoepner r. Neurology. 2024 Sep 24;103(6):e209752. doi: 10.1212/WNL.0000000000209752. Epub 2024 Aug 28. Neurology. 2024. PMID: 39197111
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.
Friedli C, Krajnc N, Hammer HN, Marti S, Zrzavy T, Evangelopoulos ME, Kapsali I, Rommer P, Berger T, Chan A, Bsteh G, Hoepner R. Friedli C, et al. Among authors: hoepner r. J Cent Nerv Syst Dis. 2024 May 5;16:11795735241249644. doi: 10.1177/11795735241249644. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38711956 Free PMC article.
114 results